Christopher Hite is Chairman & VP at Royalty Pharma plc (RPRX). They have made 1 open-market trade across 1 company since 2020, most recently 2026-09-22.
CIK 0001814238
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $2.0M since 2020, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RPRX | SELL · 10b5-1 | 2026-09-22 | 2026-09-24 | $58.53 | $5.9M | -2.7% | — | — |
| RPRX | SELL · 10b5-1 | 2026-08-18 | 2026-08-19 | $59.97 | $6.0M | -0.4% | -5.3% | — |
| RPRX | SELL · 10b5-1 | 2026-06-30 | 2026-07-02 | $56.50 | $7.3M | -2.7% | -1.2% | +0.9% |
| RPRX | SELL · 10b5-1 | 2026-06-23 | 2026-06-25 | $54.40 | $8.2M | +6.5% | +7.1% | +5.2% |
| RPRX | BUY | 2020-06-18 | 2020-06-23 | $28.00 | $2.0M | -10.2% | -16.5% | -21.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.